Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 4, 2026
Context: The filing discloses a press release regarding the U.S. Food and Drug Administration (FDA) acceptance of a resubmitted Supplemental New Drug Application (sNDA) for Joenja® (leniolisib). The application seeks approval to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory update on clinical and regulatory progress rather than a financial report.
Material Changes and Regulatory Status
- FDA Acceptance: The FDA accepted the resubmitted sNDA for Joenja following a Complete Response Letter (CRL) received on January 30, 2026, and a Type A meeting on March 26, 2026.
- Dosing Scope: The resubmission targets pediatric patients weighing 27 kg or more, seeking approval for 40 mg and 50 mg twice-daily dosing.
- PDUFA Date: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026.
- Future Filings: A separate sNDA for lower doses for patients weighing less than 27 kg is planned for the second half of 2026.
Guidance, Outlook, and Clinical Data
Clinical Support: The resubmission is supported by positive data from an open-label, multinational, single-arm Phase III study in children aged 4 to 11 years. Key findings include:
- Improvements over 12 weeks in reduced lymphadenopathy and increased naïve B cells.
- Consistency with improvements previously reported in adolescent and adult patients.
- Safety profile: All treatment-emergent adverse events were mild to moderate; no drug-related serious adverse events were reported.
Management Commentary: CEO Fabrice Chouraqui stated the acceptance brings the company closer to making Joenja available to younger patients, addressing a significant unmet need in the pediatric APDS population.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the possibility that actual results may differ from expectations due to regulatory, clinical, or commercial uncertainties. Approval is not guaranteed despite the acceptance of the resubmission.
Investor Verification Checklist
- Verify the PDUFA target action date of October 24, 2026, for the 4-11 year age group.
- Monitor the timeline for the separate sNDA submission for patients weighing less than 27 kg (planned for H2 2026).
- Review the 2025 Annual Report (Form 20-F) for detailed financial health and cash runway, as this 6-K does not contain financial statements.
- Assess the competitive landscape for APDS treatments in the U.S. pediatric market.